What is Dermata Therapeutics Inc's earnings per share (EPS)?

Dermata Therapeutics Inc (DRMA) reported diluted earnings per share of $-8.16 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Dermata Therapeutics Inc Financials

DRMA

Source SEC Filings (10-K/10-Q) Updated Mar 26, 2026 Currency USD FYE March

This page shows Dermata Therapeutics Inc (DRMA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

1/9

Dermata Therapeutics Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

1.03x

For every $1 of reported earnings, Dermata Therapeutics Inc generates $1.03 in operating cash flow (-$7.8M OCF vs -$7.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$7.6M

YoY+38.5%

Dermata Therapeutics Inc reported -$7.6M in net income in fiscal year 2025. This represents an increase of 38.5% from the prior year.

EPS (Diluted)

$-8.16

Dermata Therapeutics Inc earned $-8.16 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 1.6% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$7.5M

YoY+137.9%

5Y CAGR+70.0%

Dermata Therapeutics Inc held $7.5M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

Dermata Therapeutics Inc had 4M shares outstanding in fiscal year 2025. This represents an increase of 1497.8% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-121.4%

YoY+665.7pp

Dermata Therapeutics Inc's ROE was -121.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 665.7 percentage points from the prior year.

Capital Allocation

R&D Spending

$2.9M

YoY-64.3%

5Y CAGR+12.8%

Dermata Therapeutics Inc invested $2.9M in research and development in fiscal year 2025. This represents a decrease of 64.3% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

DRMA Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$2.9M-64.3%	$8.2M+101.6%	$4.1M-28.0%	$5.7M+63.4%	$3.5M+115.2%	$1.6M
SG&A Expenses	$4.8M+12.4%	$4.3M+8.5%	$4.0M-1.3%	$4.0M-8.5%	$4.4M+181.0%	$1.6M
Operating Income	-$7.8M+37.9%	-$12.5M-55.6%	-$8.0M+16.9%	-$9.7M-23.1%	-$7.9M-147.6%	-$3.2M
Interest Expense	N/A	N/A	N/A	$64K+39.4%	$46K-76.9%	$197K
Income Tax	N/A	$0	$0	$0	$0	$0
Net Income	-$7.6M+38.5%	-$12.3M-57.6%	-$7.8M+18.9%	-$9.6M-21.6%	-$7.9M-144.2%	-$3.2M
EPS (Diluted)	$-8.16	$-8.03+79.9%	$-39.99	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$504K-18.4%	$618K-51.8%	$1.3M	N/A	$2.4M+19.5%	$2.0M+25.5%	$1.6M	N/A
SG&A Expenses	$1.3M+8.8%	$1.2M+9.1%	$1.1M	N/A	$824K-5.8%	$875K-45.4%	$1.6M	N/A
Operating Income	-$1.8M+0.7%	-$1.8M+24.2%	-$2.3M	N/A	-$3.2M-11.9%	-$2.9M+10.0%	-$3.2M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$1.7M+0.5%	-$1.7M+26.2%	-$2.3M	N/A	-$3.2M-12.2%	-$2.8M+9.7%	-$3.1M	N/A
EPS (Diluted)	$-1.65+0.6%	$-1.66	$-0.45	N/A	$-20.41+51.2%	$-41.82	$-7.06	N/A

DRMA Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$7.9M+122.5%	$3.5M-55.7%	$8.0M+14.9%	$6.9M-40.3%	$11.6M+1819.9%	$605K
Current Assets	N/A	N/A	N/A	N/A	$11.6M+1819.9%	$605K
Cash & Equivalents	$7.5M+137.9%	$3.2M-57.5%	$7.4M+19.2%	$6.2M-42.2%	$10.8M+1936.0%	$530K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.6M-16.8%	$2.0M+21.5%	$1.6M+76.0%	$923K-39.2%	$1.5M-59.9%	$3.8M
Current Liabilities	N/A	N/A	N/A	N/A	$1.5M-59.9%	$3.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$6.2M+298.7%	$1.6M-75.4%	$6.4M+5.5%	$6.0M-40.4%	$10.1M+418.0%	-$3.2M
Retained Earnings	-$73.2M-11.5%	-$65.7M-23.0%	-$53.4M-17.1%	-$45.6M-26.7%	-$36.0M-28.1%	-$28.1M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$5.1M-23.6%	$6.6M-33.6%	$10.0M+183.1%	$3.5M-47.2%	$6.7M+27.7%	$5.2M+1.1%	$5.2M-35.1%	$8.0M
Current Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cash & Equivalents	$4.7M-28.0%	$6.5M-33.3%	$9.7M+207.4%	$3.2M-48.5%	$6.1M+24.2%	$4.9M+4.5%	$4.7M-36.4%	$7.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.1M+8.3%	$1.0M-62.0%	$2.7M+37.1%	$2.0M+1.4%	$1.9M+1.4%	$1.9M+39.9%	$1.4M-15.5%	$1.6M
Current Liabilities	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$4.0M-29.5%	$5.6M-23.1%	$7.3M+367.7%	$1.6M-67.1%	$4.7M+42.9%	$3.3M-12.9%	$3.8M-40.1%	$6.4M
Retained Earnings	-$71.4M-2.4%	-$69.7M-2.5%	-$68.0M-3.5%	-$65.7M-5.0%	-$62.5M-5.3%	-$59.4M-5.0%	-$56.5M-5.9%	-$53.4M

DRMA Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$7.8M+30.1%	-$11.1M-73.2%	-$6.4M+27.5%	-$8.8M-55.2%	-$5.7M-41.3%	-$4.0M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$12.1M+76.0%	$6.9M-9.5%	$7.6M+77.8%	$4.3M-73.2%	$16.0M+521.8%	$2.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$1.8M+33.0%	-$2.7M-39.1%	-$1.9M+32.2%	-$2.9M+16.6%	-$3.4M-60.8%	-$2.1M+21.4%	-$2.7M-135.7%	-$1.1M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	-$13K+97.6%	-$548K-106.5%	$8.5M+12484.4%	-$69K-101.5%	$4.6M+97.3%	$2.3M	$0-100.0%	$2.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

DRMA Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-121.4%+665.7pp	-787.1%-664.5pp	-122.6%+37.0pp	-159.6%-81.4pp	-78.2%	N/A
Return on Assets	-96.1%+251.6pp	-347.7%-250.0pp	-97.7%+40.7pp	-138.4%-70.4pp	-68.0%+466.6pp	-534.6%
Current Ratio	N/A	N/A	N/A	N/A	7.66+7.5	0.16
Debt-to-Equity	0.26-1.0	1.26+1.0	0.26+0.1	0.150.0	0.15+1.3	-1.19
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-42.7%-12.4pp	-30.3%+1.3pp	-31.6%	N/A	-66.9%+18.3pp	-85.3%-2.9pp	-82.3%	N/A
Return on Assets	-33.4%-7.7pp	-25.6%-2.6pp	-23.0%	N/A	-47.4%+6.6pp	-54.0%+6.5pp	-60.5%	N/A
Current Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Debt-to-Equity	0.28+0.1	0.18-0.2	0.37-0.9	1.26+0.9	0.41-0.2	0.58+0.2	0.36+0.1	0.26
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Biodexa Pharmaceuticals plc BDRX

$2.8M

Entero Therapeutics ENTO

$10.1M

Silexion Therapeutics Corp SLXN

$4.0M

THERIVA BIOLOGICS INC TOVX

$10.6M

Galecto Inc. GLTO

$1.7B

Frequently Asked Questions

Is Dermata Therapeutics Inc profitable?

No, Dermata Therapeutics Inc (DRMA) reported a net income of -$7.6M in fiscal year 2025.

What is Dermata Therapeutics Inc's return on equity (ROE)?

Dermata Therapeutics Inc (DRMA) has a return on equity of -121.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Dermata Therapeutics Inc's operating cash flow?

Dermata Therapeutics Inc (DRMA) generated -$7.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Dermata Therapeutics Inc's total assets?

Dermata Therapeutics Inc (DRMA) had $7.9M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Dermata Therapeutics Inc spend on research and development?

Dermata Therapeutics Inc (DRMA) invested $2.9M in research and development during fiscal year 2025.

How many shares does Dermata Therapeutics Inc have outstanding?

Dermata Therapeutics Inc (DRMA) had 4M shares outstanding as of fiscal year 2025.

What is Dermata Therapeutics Inc's debt-to-equity ratio?

Dermata Therapeutics Inc (DRMA) had a debt-to-equity ratio of 0.26 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Dermata Therapeutics Inc's return on assets (ROA)?

Dermata Therapeutics Inc (DRMA) had a return on assets of -96.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Dermata Therapeutics Inc's cash runway?

Based on fiscal year 2025 data, Dermata Therapeutics Inc (DRMA) had $7.5M in cash against an annual operating cash burn of $7.8M. This gives an estimated cash runway of approximately 12 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Dermata Therapeutics Inc's Piotroski F-Score?

Dermata Therapeutics Inc (DRMA) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Dermata Therapeutics Inc's earnings high quality?

Dermata Therapeutics Inc (DRMA) has an earnings quality ratio of 1.03x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.